Free tool
Rare disease stocks
We cover 29 companies grouped under the Rare disease theme. The median market value in the group is $10.01B. Across the group, the median move over the past trading day is +0.70%. 43% of the 28 with a 200-day average trade above it. Price change over the past year runs from −89.4% to +120.4% across the middle 80 percent of the group, with a median of −6.3%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
29 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | 469.95 EUR | +10.56% | +22.24% | +40.14% | Nov 2, 2026 |
| VRTX | Vertex Pharmaceuticals Incorporated | $552.85 | +15.42% | +22.28% | +42.14% | Nov 2, 2026 |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $554.44 | +1.12% | +23.31% | +42.39% | Nov 2, 2026 |
| ARGX | argenx SE | $1,019.49 | +14.70% | +21.37% | +50.52% | Oct 22, 2026 |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $240.20 | −4.67% | −39.64% | −46.85% | Oct 29, 2026 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $240.08 | −13.76% | −40.01% | −45.88% | Oct 29, 2026 |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | 200.50 EUR | −20.91% | −41.22% | −11.75% | Oct 29, 2026 |
| INSM | Insmed Incorporated | $123.89 | +18.29% | −30.05% | −3.45% | Oct 29, 2026 |
| BBIO | BridgeBio Pharma, Inc. | $80.40 | −4.42% | +2.77% | +70.01% | Oct 28, 2026 |
| 0JAV.L | Insmed Incorporated | $125.32 | +0.69% | −28.09% | −6.25% | Oct 29, 2026 |
| BMRN | BioMarin Pharmaceutical Inc. | $66.12 | +9.71% | +11.22% | +13.03% | Oct 26, 2026 |
| CYTK | Cytokinetics, Incorporated | $77.46 | −3.92% | +25.48% | +109.29% | Nov 5, 2026 |
| KYMR | Kymera Therapeutics, Inc. | $126.64 | +15.07% | +74.05% | +202.82% | Nov 3, 2026 |
| ABVX.PA | ABIVAX Société Anonyme | 98.10 EUR | −9.83% | −14.70% | +42.59% | Sep 21, 2026 |
| PTGX | Protagonist Therapeutics, Inc. | $150.59 | +11.09% | +72.73% | +164.75% | Nov 5, 2026 |
| GOSS | Gossamer Bio, Inc. | $0.20 | +2.76% | −92.90% | −91.33% | Nov 4, 2026 |
| SPRO | Spero Therapeutics, Inc. | $1.23 | +4.24% | −47.66% | −33.51% | Nov 12, 2026 |
| ATYR | aTyr Pharma, Inc. | $0.57 | +16.33% | −24.90% | −88.95% | Nov 5, 2026 |
| SCYX | SCYNEXIS, Inc. | $5.19 | +45.38% | +712.21% | +514.20% | Nov 4, 2026 |
| MCRB | Seres Therapeutics, Inc. | $5.00 | +3.09% | −67.00% | −74.00% | Nov 4, 2026 |
| MREO | Mereo BioPharma Group plc | $0.28 | −6.75% | −44.78% | −83.82% | Nov 9, 2026 |
| QNCX | Quince Therapeutics, Inc. | $30.93 | +73.28% | +3.10% | +95.76% | Nov 12, 2026 |
| JSPR | Jasper Therapeutics, Inc. | $0.72 | +3.78% | −60.86% | −75.67% | Nov 10, 2026 |
| TVRD | Tvardi Therapeutics, Inc. | $1.82 | −28.35% | −55.39% | −93.77% | Nov 12, 2026 |
| RVX.TO | Resverlogix Corp. | 0.11 CAD | −4.55% | +5.00% | +5.00% | Nov 12, 2026 |
| INM | InMed Pharmaceuticals Inc. | $1.44 | −12.20% | +28.57% | −35.43% | Sep 23, 2026 |
| JAGX | Jaguar Health, Inc. | $0.92 | −7.51% | −97.35% | −98.52% | Nov 12, 2026 |
| XRTX | XORTX Therapeutics Inc. | $2.26 | +11.88% | −20.70% | −44.74% | Nov 12, 2026 |
| APLI.TO | Appili Therapeutics Inc. | 0.02 CAD | +50.00% | −40.00% | −25.00% | Nov 12, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.